The Shift in Global Drug Development

April 30, 2026

1:03

Did you know China has just leapfrogged the US in clinical trial output? It’s not just about volume — it's fueled by major regulatory reforms that sped up drug approval processes. According to Cremieux on the a16z podcast, China’s rapid rise isn’t accidental; it’s a strategic shift, with new policies making it easier for biotech companies to innovate and test new drugs faster. Meanwhile, the US is facing pressure to adapt — if it wants to stay ahead in biomedical innovation, it’ll need to rethink its regulatory landscape too. Now, here’s where it gets interesting — this isn’t just a story about one country winning. It’s a wake-up call for the US to embrace more flexible, globally competitive approaches if it hopes to keep its edge. As content+a16zpodcast@a16z.com points out, the future of drug development depends on how quickly and efficiently regions can innovate and adapt. If this pattern holds, the nations that foster agility, not certainty, will lead the next wave of breakthroughs.

Theo Jaffee and Gabriel Dickinson speak with Cremieux about China’s rapid rise to the top of global clinical trial output. They discuss the regulatory reforms that accelerated China’s progress, the surge in novel drug development, and what the US would need to change to stay competitive in biomedical innovation.

Resources:

Follow Cremieux on X: https://x.com/cremieuxrecueil

Follow Theo on X: https://x.com/theojaffee

Follow Gabriel on X: https://x.com/gbrl_dick

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Audio Transcript